Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 6:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 962 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Obstructive Airway Disease Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Social Work Intervention Focused on Transitions

NCT02232126
View directory record Official record
Conditions
Study Focus: 30-day Rehospitalizations Among At-risk Older Adults Randomized to a Social Work-driven Care Transitions Intervention, Heart Disease, Diabetes, Hypertension, Cancer, Depression, Asthma, Chronic Heart Failure, Chronic Obstructive Pulmonary Disease, Stroke
Interventions
SWIFT home intervention
Other
Lead sponsor
University of Southern California
Other
Eligibility
65 Years to 110 Years
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Los Angeles, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 1, 2026, 6:24 PM EDT
Completed Phase 2 Interventional

Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)

NCT02302417
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Spirometry, ACOS clinical questionnaire
Procedure · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
12
States / cities
Newport Beach, California • Upland, California • Sunset, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 1, 2026, 6:24 PM EDT
Completed Not applicable Interventional Results available

INtervention Study In overweiGHT Patients With COPD

NCT02634268
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Obesity, Weight Loss, Life Style, Overweight
Interventions
Lifestyle Intervention
Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
40 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
39
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 1, 2026, 6:24 PM EDT
Completed No phase listed Observational

Mucus Dehydration and Evolution of Chronic Obstructive Pulmonary Disease (COPD) Lung Disease

NCT00903955
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Interventions
7% hypertonic saline
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 82 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 1, 2026, 6:24 PM EDT
Not listed No phase listed Observational

Outcomes Data of Adipose Stem Cells to Treat Chronic Obstructive Pulmonary Disease

NCT02348060
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
StemGenex
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 1, 2026, 6:24 PM EDT
Completed No phase listed Observational

Portable Oxygen Concentrator to Improve Quality of Life in Chronic Obstructive Pulmonary Disease

NCT01948544
View directory record Official record
Conditions
COPD
Interventions
Not listed
Lead sponsor
StratiHealth
Industry
Eligibility
65 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Oceanside, California • Vista, California • Westminster, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 1, 2026, 6:24 PM EDT
Completed Not applicable Interventional

A Study of Tobacco Smoke and Children With Respiratory Illnesses

NCT03062709
View directory record Official record
Conditions
Bronchiolitis, Pneumonia, Reactive Airway Disease, Asthma, Tobacco Smoking, Tobacco Cessation, Bronchopulmonary Dysplasia
Interventions
Breathe Easy Coalition written materials, Maine Tobacco Helpline, Urine cotinine testing
Behavioral · Diagnostic Test
Lead sponsor
MaineHealth
Other
Eligibility
Up to 10 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 1, 2026, 6:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 3)

NCT03583099
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
COPD plus CAPTURE education and patient-level information, COPD Education Only
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
45 Years to 80 Years
Enrollment
2,004 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 1, 2026, 6:24 PM EDT
Completed Phase 3 Interventional Results available

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

NCT02138916
View directory record Official record
Conditions
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab Arm A, Benralizumab Arm B, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
138
States / cities
Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 1, 2026, 6:24 PM EDT
Completed Phase 2 Interventional Results available

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

NCT04631016
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis
Interventions
Tozorakimab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Sheffield, Alabama • Newport Beach, California • Newark, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 1, 2026, 6:24 PM EDT
Completed Phase 4 Interventional Results available

Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease

NCT00984659
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone propionate/salmeterol combination product, Salmeterol, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
39
States / cities
Jasper, Alabama • Mobile, Alabama • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 1, 2026, 6:24 PM EDT
Completed Phase 4 Interventional Results available

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

NCT02799784
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, TIO/OLO, Albuterol/salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Clearwater, Florida • Orlando, Florida • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 1, 2026, 6:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)

NCT01398943
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tetrahydrobiopterin (BH4), Antioxidant Cocktail
Drug · Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 1, 2026, 6:24 PM EDT
Completed Phase 2 Interventional Results available

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01587079
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT003, PT001, PT005, Tiotropium inhalation powder
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
19
States / cities
Glendale, Arizona • Rancho Mirage, California • Waterbury, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Oct 1, 2026, 6:24 PM EDT
Active, not recruiting Phase 2 Interventional

Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

NCT05612035
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Frespaciguat, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
40 Years to 85 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
18
States / cities
San Francisco, California • Aurora, Colorado • Sebring, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 1, 2026, 6:24 PM EDT
Not listed No phase listed Observational

Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)

NCT01074515
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
40 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
4
States / cities
San Antonio, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 1, 2026, 6:24 PM EDT
Recruiting No phase listed Observational

Evaluation Of The Lung Microbiome In NTM Bronchiectasis

NCT02779478
View directory record Official record
Conditions
Nontuberculous Mycobacteria, Bronchiectasis
Interventions
Bronchoscopy
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 1, 2026, 6:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust

NCT03089515
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Lower Respiratory Disease
Interventions
Cardio-Pulmonary Exercise Testing (CPET)
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 1, 2026, 6:24 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT02275052
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI DPI, Placebo DPI, Albuterol/salbutamol MDI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Jasper, Alabama • Saint Charles, Missouri • Charlotte, North Carolina + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 1, 2026, 6:24 PM EDT
Completed Phase 3 Interventional Results available

Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)

NCT02006732
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
olodaterol, tiotropium, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
809 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
20
States / cities
Jasper, Alabama • Stamford, Connecticut • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 1, 2026, 6:24 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00856193
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Placebo, NVA237
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Oct 1, 2026, 6:24 PM EDT
Recruiting No phase listed Observational

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

NCT06122077
View directory record Official record
Conditions
Lung Cancer Diagnosis
Interventions
blood draw
Diagnostic Test
Lead sponsor
Freenome Holdings Inc.
Industry
Eligibility
50 Years and older
Enrollment
20,000 participants
Timeline
2023 – 2027
U.S. locations
36
States / cities
Los Angeles, California • Stamford, Connecticut • DeLand, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 1, 2026, 6:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

NCT05830071
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
CHF5993, CHF5259, Moxifloxacin 400mg, CHF5993 Placebo
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 1, 2026, 6:24 PM EDT
Recruiting Phase 2 Interventional

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia

NCT07037836
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease), Hypoxemia
Interventions
Inhaled Treprostinil (Tyvaso Nebulizer)
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 1, 2026, 6:24 PM EDT